Pennsylvania is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Intratumoral PH-762 for Cutaneous Carcinoma
NCT06014086
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: UPMC Department of Dermatology, Pittsburgh, Pennsylvania
Conditions: Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
Register for Updates
Bright Light Therapy for OSA
NCT05917119
Recruiting
Persistent daytime symptoms of sleepiness in individuals with obstructive sleep apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. This study will explore the role of Bright Light Therapy (BLT),... Read More
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
01/24/2025
Locations: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania
Conditions: Obstructive Sleep Apnea
Register for Updates
A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing
NCT06625385
Recruiting
The purpose of this clinical study is to obtain post-market safety and efficacy data when the V.A.C.® Peel and Place dressing is used in conjunction with 3M™ V.A.C.® Therapy.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
01/23/2025
Locations: St. Luke's University Hospital, Bethlehem, Pennsylvania
Conditions: Wound
Register for Updates
A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis
NCT06159725
Recruiting
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF). The main questions the study aims to answer are: * Are single doses of CMTX-101 IV infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single doses of CMTX-101 * Do single doses of CMTX-101 induce development of ant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: PennState Health, Hershey, Pennsylvania
Conditions: Persistent Infection, Cystic Fibrosis
Register for Updates
Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients
NCT05688423
Recruiting
The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervention approach in patients hospitalized with severe injection-related infections (SIRI) who use drugs. The main question this study aims to answer is whether this intervention approach will be associated with lower mortality and fewer hospital readmissions. Participants will participate in the integrated SUD/ID care team intervention (SIRI Team). Rese... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Injection Site Infection, Substance Use Disorders
Register for Updates
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/23/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
Register for Updates
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
NCT05271578
Recruiting
To examine vascular reactivity and inflammatory biomarkers via quantitative magnetic resonance imaging (MRI) and blood serum, respectively, in a crossover study where active vapers (electronic cigarette users) and smokers will undergo three separate acute exposure-episodes of electronic cigarette +/- nicotine and tobacco-cig. The MRI exams and blood draws will be performed pre- and post-exposure. The results will be compared against baseline values derived from a group of non-smokers/non-vapers,... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Vascular Reactivity, Serum Biomarkers
Register for Updates
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
NCT04680468
Recruiting
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and mainten... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Myeloma
Register for Updates
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542
Recruiting
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Register for Updates
Deep Brain Stimulation Effects in Patients with Opioid Use Disorder
NCT04354077
Recruiting
This is a pilot study to evaluate the safety and efficacy of deep brain stimulation (DBS) of the nucleus accumbens (NAc) as adjunctive treatment for treatment-refractory opioid use disorder. This study will include 3 individuals with opioid use disorder and relapsing opioid use despite active participation in a drug addiction treatment program.
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
01/23/2025
Locations: AHN Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Opioid-use Disorder
Register for Updates
iLookOut for Child Abuse: Micro-learning to Improve Knowledge Retention
NCT04324619
Recruiting
This proposed randomized controlled trial will examine whether gamified micro-learning is a feasible and effective way to promote long-term learning about child abuse and its reporting. After completing the interactive online learning program, iLookOut for Child Abuse, early childhood professionals will receive brief (5-10 minute) gamified learning exercises to complete on their smart-phones. By measuring knowledge (and other outcomes) over time, the investigators will determine how much knowled... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/23/2025
Locations: Penn State Milton S. Hershey Medical Center / Penn State College of Medicine, Hershey, Pennsylvania
Conditions: Child Abuse
Register for Updates
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
NCT02225301
Recruiting
Phase 1 was a randomized control trial that used a test-retest model to evaluate the impact of iLook Out for Child Abuse, an online, interactive learning module about reporting suspected child abuse. Delivered via a learning management system to early childhood professionals who work with infants and young children, this study assessed iLookOut's effect on 1) knowledge about reporting suspected child abuse; 2) attitudes toward reporting suspected child abuse; and 3) preparedness to protect child... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Penn State Milton S. Hershey Medical Center / Penn State College of Medicine, Hershey, Pennsylvania
Conditions: Child Abuse, Child Neglect, Child Maltreatment
Register for Updates